Company Performance Metrics
Hanano Technologies develops oncology therapeutics based on camelid-derived single-domain antibodies, also known as nanobodies. The company focuses on two main modalities: antibody-drug conjugates, where nanobodies are linked to cytotoxic payloads to selectively destroy tumour cells, and radiopharmaceuticals, where nanobodies are conjugated to
diagnostic or therapeutic radionuclides for targeted imaging and treatment of solid tumours. Its platform uses artificial intelligence and machine learning to model nanobody–antigen interactions, optimise conjugation sites, and predict pharmacokinetics and biodistribution. These computational tools are combined with experimental expertise in structural biology, nuclear medicine, and clinical-grade nanobody production. Hanano Technologies aims to generate precision-targeted drug candidates with controlled biodistribution and reduced off-target exposure.
